AnaptysBio To Save $10 Million After Discontinuing Ulcerative Colitis Study
1. Rosnilimab failed to meet primary efficacy endpoints in ulcerative colitis trial. 2. Phase 2 trial discontinuation may save AnaptysBio over $10 million. 3. Rosnilimab showed safety but low remission rates at Week 12. 4. Future updates on rosnilimab for rheumatoid arthritis expected in H1 2026. 5. Anaptys plans to separate biopharma assets from royalty revenues in 2026.